Human Tissue Research Arbitration

1. Introduction

Human tissue research arbitration concerns disputes arising from contracts and research arrangements involving human biological materials such as:

blood;

plasma;

DNA;

stem cells;

tumour samples;

bone marrow;

organs and tissues;

umbilical-cord blood;

umbilical-cord tissue;

biopsy specimens;

human-cell lines;

genomic material; and

biological specimens stored in biobanks.

It sits at the intersection of arbitration law, biomedical research, informed consent, bioethics, intellectual property, privacy/data protection, contract law and medical regulation.

A typical arrangement may look like:

Patient/Donor → Hospital/Collection Centre → University/Research Institution → Biobank → Pharmaceutical/Biotechnology Company

Disputes can arise at any point in this chain.

Importantly, there is not yet a large reported body of decisions specifically called "human tissue research arbitration." The most useful authorities therefore fall into two groups:

Direct or near-direct arbitration authorities involving human tissue, cadaveric tissue, cord blood or biological-sample contracts, and

Major human-tissue research cases that establish the substantive rules an arbitral tribunal would likely have to apply.

I distinguish those categories below rather than presenting ordinary tissue litigation as if it were an arbitration award.

2. What Is Human Tissue Research Arbitration?

Human tissue research arbitration occurs where the parties have agreed to arbitration for disputes concerning the collection, storage, transfer, research, licensing, commercialization, processing or destruction of human biological materials.

For example:

Research collaboration

A university supplies tumour samples to a biotechnology company.

Biobank agreement

A hospital transfers thousands of blood samples to a research repository.

Tissue-processing agreement

A tissue-recovery organisation supplies human tissue to a medical-device manufacturer.

Stem-cell agreement

Parents contract with a private bank to collect and preserve umbilical-cord blood and tissue.

Pharmaceutical research

Patients' biological samples are used to develop a diagnostic test or therapeutic product.

3. Why Arbitration Is Particularly Relevant

Human tissue disputes can involve extremely sensitive information.

The arbitration may concern:

patient identity;

genetic information;

disease status;

family medical history;

DNA sequences;

clinical records;

research protocols;

proprietary cell lines;

patents;

trade secrets;

commercialisation strategies.

Arbitration offers potential advantages of:

confidentiality;

specialist arbitrators;

expert evidence;

flexible procedures;

cross-border enforceability;

preservation of commercial relationships.

However, arbitration cannot override mandatory laws governing human-subject research, consent, privacy, public health or human biological materials.

4. Major Types of Human Tissue Research Disputes

A. Ownership disputes

Who owns the biological sample?

patient;

donor;

hospital;

university;

researcher;

biobank;

biotechnology company?

B. Consent disputes

Was the donor informed that the sample would be:

stored;

transferred;

genetically sequenced;

commercialised;

shared internationally?

C. Commercialisation disputes

A donor provides tissue for research and the resulting technology becomes extremely valuable.

Can the donor claim:

royalties?

ownership?

compensation?

profit-sharing?

D. Research collaboration disputes

Universities and companies may disagree over:

research milestones;

ownership;

publications;

patents;

licensing;

confidentiality.

E. Biobank disputes

Examples include:

failure to collect samples;

improper storage;

destruction;

contamination;

failure to transfer samples;

inadequate temperature control.

5. Case Law 1 — LaBarge v. Elutia, Inc.

U.S. District Court, Southern District of California, 2025

This is one of the most directly relevant recent authorities.

The underlying litigation concerned ViBone, a human-tissue allograft consisting of cryopreserved bone matrix. The tissue had been recovered and processed by DCI Donor Services and used in a spinal procedure.

DCI filed contractual crossclaims against Aziyo/Elutia concerning:

breach of contract;

express indemnity;

equitable indemnity;

contribution; and

declaratory relief.

Aziyo sought to compel arbitration under a Cadaveric Tissue Recovery and Services Agreement containing a multi-step dispute-resolution provision.

The court examined whether the clause required arbitration after negotiation and mediation. It held that the agreement's language permitted a party to demand arbitration and granted the motion to compel arbitration. (Justia Law)

Legal principle

The case demonstrates that an agreement concerning the recovery and supply of human tissue can contain an enforceable arbitration mechanism even where the underlying dispute ultimately arises from an injury allegedly caused by the tissue product.

Importance

This is directly relevant to:

tissue banks;

donor organisations;

allograft manufacturers;

hospitals;

medical-device companies;

indemnity arrangements.

It also demonstrates the importance of clearly drafting multi-tier dispute-resolution clauses.

6. Case Law 2 — Blakely v. Elutia, Inc.

U.S. District Court, Southern District of California, 2026

This is another highly significant and very recent human-tissue arbitration authority.

The case involved a spinal surgery in which the plaintiff was implanted with ViBone, a human-tissue allograft consisting of cryopreserved bone matrix.

DCI Donor Services filed a crossclaim against Elutia concerning:

breach of contract;

indemnity;

contribution; and

declaratory relief.

Elutia sought arbitration under a Cadaveric Tissue Recovery and Services Agreement. The agreement required negotiation and mediation before arbitration and stated that either party could demand arbitration if mediation failed.

The court held that the word "may" in the arbitration provision did not make arbitration merely optional. Once a party timely elected arbitration after the contractual preliminary steps, arbitration became mandatory. The court therefore granted the motion to compel arbitration. (Justia Law)

Legal significance

The case provides a valuable drafting lesson:

Words such as "may" do not necessarily make arbitration permissive.

The surrounding contractual language must be considered.

Application

A human-tissue research contract should therefore avoid ambiguity by stating:

"If mediation does not resolve the dispute, either party may demand arbitration, and upon such demand the dispute shall be finally resolved by arbitration."

7. Case Law 3 — Smt. Swarna Kataru v. Life Cell International Pvt. Ltd.

Indian consumer dispute concerning cord tissue/stem-cell preservation

This case concerns a private cord-blood and cord-tissue preservation agreement.

LifeCell argued that the parties' agreement contained an arbitration clause and therefore the consumer complaint was not maintainable. The dispute involved the contractual arrangements for preservation of cord tissue and blood.

The case is particularly relevant because it demonstrates the tension between:

a contractual arbitration clause

and

statutory consumer remedies.

The arbitration objection was considered in the consumer proceedings rather than simply being treated as automatically dispositive. (Indian Kanoon)

Legal significance

A human-tissue storage company cannot assume that inserting an arbitration clause into its standard contract automatically eliminates every statutory remedy available to a consumer.

Application

This is important for:

stem-cell banks;

cord-blood banks;

tissue-storage companies;

genetic testing companies.

The tribunal must consider whether mandatory statutory rights remain available notwithstanding the arbitration agreement.

8. Case Law 4 — Cryobanks International India Pvt. Ltd. v. Sonika Goyal & Anr.

National Consumer Disputes Redressal Commission, 2026

This is a particularly important Indian authority concerning cord blood and umbilical-cord stem cells.

The parents enrolled in a private family cord-blood and umbilical-cord stem-cell storage programme. The company supplied a collection kit and contractual documentation.

The dispute arose because the cord blood and stem-cell material was not collected at the time of delivery.

Cryobanks argued that the agreement allocated responsibility for collection to the parents/physician and pointed to an arbitration clause stating that disputes would be settled through arbitration. The consumer forum nevertheless proceeded with the consumer complaint. (Indian Kanoon)

The National Commission ultimately upheld the findings of deficiency in service and the compensation awarded by the lower consumer fora. It dismissed the revision petitions. (Indian Kanoon)

Legal significance

This case is highly relevant to tissue-research and biobanking contracts because it illustrates:

contractual allocation of collection responsibility;

sample-collection logistics;

consent documentation;

contractual limitations of liability;

arbitration clauses; and

statutory consumer remedies.

It also demonstrates that the failure to collect a biological sample can itself generate substantial legal consequences, even before research begins.

9. Case Law 5 — Moore v. Regents of the University of California

California Supreme Court, 1990

This is the foundational human-tissue research case.

John Moore was treated for hairy-cell leukemia at UCLA. His physician removed Moore's spleen and subsequently obtained additional biological materials.

The physician and researchers developed a valuable cell line from Moore's cells and entered into commercial arrangements involving the resulting technology.

Moore alleged, among other things:

lack of informed consent;

breach of fiduciary duty;

conversion; and

undisclosed commercial exploitation.

The California Supreme Court held that Moore could pursue claims based on lack of informed consent and breach of fiduciary duty, but rejected his conversion claim based on ownership of the excised cells. (California Supreme Court Resources)

Central principle

A physician must disclose material interests that may affect medical judgment and the patient's decision whether to undergo treatment.

But the court did not recognise a general continuing property interest in excised cells sufficient to support conversion.

Arbitration significance

Suppose a research agreement states:

"All disputes concerning use, research or commercialisation of biological samples shall be arbitrated."

The tribunal may need to distinguish:

contractual rights;

informed-consent obligations;

fiduciary obligations;

statutory rights; and

property claims.

Moore is therefore indispensable for determining the substantive background against which the arbitration operates.

10. Case Law 6 — Greenberg v. Miami Children's Hospital Research Institute

U.S. District Court, Southern District of Florida, 2003

This is one of the most important cases involving donated human tissue and research commercialisation.

Families affected by Canavan disease supplied:

tissue;

blood;

urine;

medical information;

family information;

financial support.

The research ultimately led to identification of the Canavan gene and subsequent patenting and commercialisation.

The donors alleged:

lack of informed consent;

breach of fiduciary duty;

unjust enrichment;

fraudulent concealment;

conversion; and

misappropriation of trade secrets.

The court dismissed most of the claims but allowed the unjust-enrichment claim to proceed. (PubMed)

Legal significance

Greenberg is particularly important because it demonstrates that a research collaboration may create legal consequences beyond simple ownership of biological material.

The donors did not merely hand over tissue; they allegedly contributed:

funding;

information;

family contacts;

organisational assistance;

research support.

Arbitration application

An arbitral tribunal could therefore encounter claims concerning:

unjust enrichment;

contractual collaboration;

research contributions;

commercialisation;

royalties;

disclosure obligations.

11. Case Law 7 — Washington University v. Catalona

U.S. Court of Appeals for the Eighth Circuit, 2007

This case concerned thousands of biological samples collected for prostate-cancer research.

Dr. William Catalona had worked at Washington University and collected biological materials from numerous research participants.

When he moved institutions, many donors signed forms requesting that their samples be transferred to him.

Washington University argued that it owned the repository and biological materials.

The Eighth Circuit upheld the university's position, concluding that the research participants did not possess the proprietary interest necessary to control the samples as property and that the university owned the repository materials under the circumstances. (FindLaw)

Legal significance

The case illustrates the importance of distinguishing:

consent to research

from

ownership of biological material.

Arbitration application

A research agreement should therefore expressly state:

who owns physical specimens;

who controls the biobank;

who may transfer samples;

what happens if the researcher changes institutions;

whether donors may withdraw samples;

what happens to already-generated research results.

12. Case Law 8 — Metropolis Healthcare Ltd. v. Ranjan Path Lab

Bombay High Court, 2024

This case concerned a Diagnostic Services Agreement under which Metropolis conducted pathological testing of human samples.

The agreement contained a broad arbitration clause covering disputes concerning:

interpretation;

operation;

performance;

non-performance;

termination; and

other differences between the parties.

The Bombay High Court dealt with the arbitration application after contractual payments remained outstanding and an arbitration notice had been issued. The agreement specified Mumbai as the seat. (Indian Kanoon)

Importance to human-tissue research

Although this was not a research dispute, it is a useful Indian contractual authority because it concerns commercial testing of human samples.

It illustrates how an arbitration clause can govern relationships involving:

laboratories;

pathology providers;

hospitals;

diagnostic companies;

biological-sample processing.

It is therefore highly relevant by analogy to commercial human-tissue research contracts.

13. Summary of the Eight Authorities

14. Key Legal Issue: Who Owns Human Tissue?

This is one of the most controversial questions.

There are several possible approaches.

Model 1 — Donor ownership

The donor retains property rights.

Model 2 — Institutional custody

The hospital or university controls the physical sample.

Model 3 — Contractual control

The contract determines who can possess, transfer or use the sample.

Model 4 — No conventional property right

The donor may have consent, privacy or fiduciary rights without possessing ordinary property rights.

Moore and Catalona demonstrate why this distinction is critical. (California Supreme Court Resources)

15. Consent Is Different From Ownership

A crucial principle is:

Consent to research does not necessarily transfer ownership of every possible intellectual or commercial consequence of the research.

For example:

A patient may agree:

"My blood may be used for cancer research."

That does not necessarily answer:

Can the sample be sold?

Can it be transferred overseas?

Can DNA be sequenced?

Can it be used for commercial drug development?

Can the resulting invention be patented?

Can a cell line be created?

Can the sample be reused for unrelated research?

Those matters should be expressly addressed.

16. Secondary Use of Human Tissue

Modern research frequently involves secondary use.

A sample initially collected for:

cancer diagnosis

may later be used for:

genomic research.

This raises questions concerning whether the original consent covered the secondary purpose.

An arbitration tribunal may therefore have to examine:

original consent form;

research protocol;

institutional policies;

ethics-committee approval;

contractual terms;

applicable regulations.

17. Commercialisation of Tissue-Derived Research

Suppose:

Patient donates tumour tissue.

University performs research.

Researchers identify a molecular marker.

Biotechnology company develops a diagnostic test.

Patent is granted.

Company earns millions.

Possible dispute:

Does the patient receive anything?

The answer depends heavily on the applicable law and contractual arrangements.

Moore rejected the particular conversion theory advanced by the patient, while Greenberg illustrates how unjust-enrichment arguments can arise where donors made broader contributions to research. (California Supreme Court Resources)

18. Intellectual Property

Human-tissue research contracts frequently generate IP disputes concerning:

Patents

gene-related inventions;

diagnostic technologies;

therapeutic discoveries;

cell-based technologies.

Copyright

databases;

software;

research materials.

Trade secrets

proprietary protocols;

sequencing techniques;

cell-culture methods.

Know-how

sample preparation;

preservation;

laboratory procedures.

The contract should clearly distinguish:

biological material itself

from

inventions and information derived from that material.

19. Biobank Arbitration

A biobank may hold tens of thousands or millions of specimens.

A dispute can involve:

destruction of samples;

unauthorised transfer;

improper storage;

contamination;

loss of samples;

data breach;

failure to honour withdrawal requests;

transfer to another institution.

Washington University v. Catalona illustrates the importance of contractual and institutional rules governing control of a large research repository. (FindLaw)

20. Sample Collection and Storage

The Cryobanks case demonstrates that collection itself can be legally significant.

A tissue-storage company may promise:

collection;

transportation;

processing;

testing;

cryopreservation;

long-term storage.

Failure at any stage may cause the biological material to become unavailable permanently.

That is fundamentally different from ordinary commercial goods because:

a lost biological sample may be impossible to replace.

Therefore, damages may be difficult to quantify.

21. Confidentiality and Genetic Data

Human tissue research frequently generates:

DNA sequences;

genetic profiles;

disease information;

family relationships;

genomic risk information.

A research arbitration may therefore involve both:

Material confidentiality

Who can access the physical sample?

and

Information confidentiality

Who can access the genetic information derived from the sample?

The contract should address both.

22. Cross-Border Transfer of Tissue

International research creates additional complications.

Example:

Indian hospital → German biobank → American biotechnology company

Questions include:

Was international transfer authorised?

Did the consent permit transfer?

Which country's privacy rules apply?

Which country's research regulations apply?

Who owns the transferred specimen?

Which country's courts supervise the arbitration?

Can an award require the return or destruction of samples?

These questions should be addressed before research begins.

23. Non-Signatories

A major arbitration problem arises because the donor may not have signed the commercial research agreement.

For example:

University ↔ Pharmaceutical Company

may have an arbitration clause.

But:

Patient/donor

may not be a party.

If the patient later claims that the company misused the tissue, the company cannot automatically assume that the donor is bound by the university-company arbitration clause.

Conversely, a donor cannot necessarily rely on an arbitration agreement to which they never became a party.

This is why human-tissue agreements should carefully define:

parties;

beneficiaries;

donors;

researchers;

laboratories;

commercial partners.

24. Expert Evidence

Human-tissue arbitration often requires experts in:

pathology;

molecular biology;

genetics;

genomics;

stem-cell science;

bioinformatics;

biobanking;

medical ethics;

biotechnology;

intellectual property.

An arbitrator may need to determine whether:

a particular tissue sample generated an invention;

two samples were genetically identical;

a research result was derived from the disputed specimen;

contamination occurred;

storage failure destroyed viability.

25. Damages

Potential damages include:

Direct losses

Cost of replacement research or samples.

Research delay

Additional time required to reproduce experiments.

Commercial losses

Lost licensing opportunities.

Royalties

Where a contractual royalty arrangement exists.

Storage costs

Costs associated with preservation and transfer.

Data-related losses

Costs resulting from loss or misuse of genomic data.

Unjust enrichment

Potentially relevant where one party obtains a benefit from another's contribution without appropriate contractual justification.

Greenberg is particularly relevant to this last category. (PubMed)

26. Emergency Measures

Human tissue disputes may require urgent relief.

An arbitral tribunal or competent court may be asked to preserve:

tissue samples;

cell lines;

DNA extracts;

laboratory records;

sequencing data;

research notebooks;

electronic databases.

For example, if a university proposes destroying samples after termination of a research agreement, the other party may seek urgent relief preventing destruction pending arbitration.

27. Drafting an Effective Human-Tissue Arbitration Clause

A sophisticated agreement should specify:

1. Definition of biological material

Include:

tissue;

blood;

cells;

DNA;

RNA;

derivatives;

cell lines;

samples;

extracted materials.

2. Permitted research

Specify exactly what research is authorised.

3. Secondary use

State whether samples may be used for unrelated future research.

4. Commercialisation

Specify:

licensing;

royalties;

ownership;

revenue sharing.

5. Transfer

Specify whether samples may be transferred:

to affiliates;

universities;

laboratories;

foreign countries;

commercial partners.

6. Destruction/return

State what happens when the agreement terminates.

7. Data

Separate physical samples from genetic and research data.

8. Arbitration

Specify:

seat;

institution;

governing law;

number of arbitrators;

language.

9. Emergency measures

Allow urgent preservation of samples and data.

10. Confidentiality

Protect patient and research information.

28. Suggested Dispute-Resolution Structure

A particularly suitable arrangement is:

Scientific dispute

↓

Independent scientific expert

↓

Commercial/contractual dispute

↓

Senior-management negotiation

↓

Mediation

↓

Final arbitration

This avoids sending every technical disagreement immediately into a full arbitration.

29. Important Distinction: Arbitration vs Ethics Review

An arbitral tribunal should not be treated as a substitute for:

institutional ethics committees;

institutional review boards;

medical regulators;

research authorities;

public-health regulators.

For example, if a regulator prohibits use of a particular human tissue, an arbitration tribunal cannot simply declare the regulatory prohibition invalid because the parties' contract permits the research.

The tribunal may instead determine:

What contractual consequences follow from the regulatory prohibition?

That distinction is essential.

30. Indian Perspective

In India, human-tissue research can engage several legal and regulatory regimes, depending upon the nature of the research, including:

the Arbitration and Conciliation Act, 1996;

medical and biomedical research regulations;

human-subject research ethics requirements;

privacy/data-protection law;

medical-device/drug regulation;

consumer-protection legislation;

contractual principles.

The Cryobanks litigation is especially useful because it demonstrates how a biological-sample storage agreement can contain an arbitration clause while the consumer simultaneously seeks statutory remedies. (Indian Kanoon)

The Metropolis decision is useful for commercial laboratory arrangements because the Bombay High Court dealt with a broad arbitration clause in an agreement concerning pathological testing of human samples. (Indian Kanoon)

31. Key Legal Principles From the Cases

Principle 1 — Arbitration is contractual

LaBarge and Blakely show that the precise wording of the tissue-recovery agreement determines whether disputes must proceed to arbitration. (Justia Law)

Principle 2 — Biological material requires special contractual treatment

Moore demonstrates that conventional property concepts do not provide a complete answer to the legal status of excised human tissue. (California Supreme Court Resources)

Principle 3 — Research consent is fundamental

Researchers must carefully determine what the donor actually authorised.

Principle 4 — Ownership and control are separate

Catalona demonstrates that donors' consent to research does not necessarily establish ownership of the physical research repository. (FindLaw)

Principle 5 — Commercialisation creates additional disputes

Greenberg shows how donor contributions can produce claims concerning unjust enrichment and commercial exploitation. (PubMed)

Principle 6 — Arbitration may coexist with statutory remedies

The Indian cord-blood cases demonstrate that a contractual arbitration clause does not automatically eliminate every statutory remedy. (Indian Kanoon)

32. Case-Law Classification

It is important academically to classify the authorities correctly.

Direct/near-direct arbitration authorities

LaBarge v. Elutia, Inc. — 2025

Blakely v. Elutia, Inc. — 2026

Swarna Kataru v. Life Cell International Pvt. Ltd.

Cryobanks International India Pvt. Ltd. v. Sonika Goyal

Metropolis Healthcare Ltd. v. Ranjan Path Lab

Foundational human-tissue research authorities

Moore v. Regents of the University of California

Greenberg v. Miami Children's Hospital Research Institute

Washington University v. Catalona

The last three are not arbitration decisions, but they are indispensable substantive authorities for understanding the claims that may be submitted to arbitration.

33. Conclusion

Human tissue research arbitration is an emerging specialist area of life-sciences arbitration. It combines the contractual machinery of arbitration with highly sensitive questions concerning human dignity, informed consent, biological materials, genetic information, scientific research and commercialisation.

The most important issues are:

ownership and control of tissue;

informed consent;

secondary research use;

commercialisation;

patent rights;

confidentiality;

genetic data;

biobank management;

sample collection and storage;

international transfer;

non-signatory donors;

statutory consumer and regulatory rights; and

damages.

The recent LaBarge v. Elutia and Blakely v. Elutia decisions are particularly valuable because they provide actual arbitration authorities involving agreements for recovery and supply of human tissue, while Cryobanks v. Sonika Goyal demonstrates the Indian context of contractual arbitration clauses in biological-sample storage arrangements. (Justia Law)

For the substantive law of human biological materials, Moore v. Regents, Greenberg v. Miami Children's Hospital, and Washington University v. Catalona remain foundational. They demonstrate that consent, property, institutional control, research collaboration and commercialisation are legally distinct concepts and should be expressly separated when drafting a human-tissue research agreement. (California Supreme Court Resources)